CSPC Pharmaceutical Group
CSPC is a large Chinese pharma whose cancer business rests on albumin-bound paclitaxel and liposomal doxorubicin generics, an ADC pipeline and a growing list of licences to Western companies.
Overview
Domestic leader in nanoparticle albumin-bound paclitaxel (Keaili) and pegylated liposomal doxorubicin (Duomeisu); innovative pipeline includes the Nectin-4 ADC SYS6002, the Claudin 18.2 ADC SYSA1801, an EGFR ADC and a PD-1 x VEGF programme; licences include an AI-enabled discovery collaboration with AstraZeneca (June 2025) and ADC deals. Illustrates the shift of China's big generic houses into originator research.
Scorecard
All companies- approved products +12
- modalities +2
- regions +6
- registry trials +30
A microtubule poison discovered in the Pacific yew tree, among the most used chemotherapies in breast, lung, and ovarian cancer.
Doxorubicin wrapped in a fatty bubble so it reaches tumours with less heart damage; a workhorse of relapsed ovarian cancer.
Pages like this
not linked directly; found by shared links- TrialJUPITER-06
Shares Paclitaxel / nab-paclitaxel and the tag china.
- CompanyHutchmed
Shares AstraZeneca and the tag china.
- ProductSavolitinib
Shares AstraZeneca and the tag china.
- CancerKaposi sarcoma
Shares Pegylated liposomal doxorubicin, Paclitaxel / nab-paclitaxel.